To continue reading this content, please enable JavaScript in your browser settings and refresh this page. In April 2021, the FDA approved the 100th monoclonal ...

In the last few years, multispecific antibodies, such as bispecific, trispecific, and tetraspecific antibodies, have become the breakthrough stars in antibody therapeutics. Compared with conventional ...

Boehringer Ingelheim announced a license and collaboration agreement with Simcere Pharmaceuticals to develop Simcere’s ...

Extracting therapeutic antibodies from biological systems requires stringent purification processes. To reduce costs and accelerate development, novel strategies are essential ...

Researchers at Colorado State University have determined how to use artificial intelligence to modify antibodies so they act ...

A team of researchers at the Indian Institute of Technology (IIT) Roorkee on Tuesday announced the development of a ...

For therapies based on monoclonal antibodies (mAbs), bioprocessors continually search for ways to improve the development process. Machine learning (ML) offers one useful tool. As Mariano Nicolas Cruz ...

This study presents a comprehensive approach for assessing multiple quality attributes of antibody-oligonucleotide conjugates.

A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...

Monoclonal antibodies (mAbs) aid the body against autoimmune diseases and cancer, among other things. Patients have to pick ...

iBio (IBIO) in collaboration with AstralBio announced the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity ...